Date Time
Medicine by Design symposium highlights importance of convergence in regenerative medicine and human health
Researchers are poised to make unprecedented breakthroughs in human health thanks to advances in biomedical and computational sciences that have driven critical tools and technologies such as genetic engineering, synthetic biology, and artificial intelligence.
That’s the message Dr. Victor Dzau, president of the U.S. National Academy of Medicine, delivered to Medicine by Design’s fifth annual symposium on Dec. 7 and 8.
The virtual event, which attracted more than 500 registrants from across North America, focused on the theme of better science through convergence – the integration of approaches from engineering, science, medicine and other fields to expand knowledge and spark innovation.
Credit: n/a
December 22 - Three clinical trial platforms working together to test the effects of full doses of anticoagulants (blood thinners) in COVID-19 patients have paused enrollment for one group of patients. Among critically ill COVID-19 patients requiring intensive care unit (ICU) support, full dose anticoagulation drugs did not improve outcomes. Enrollment continues for moderately ill hospitalized COVID-19 patients in the trials.
As is normal for clinical trials, these trials are overseen by independent boards that routinely review the data and are composed of experts in ethics, biostatistics, clinical trials, and blood clotting disorders. Informed by the deliberations of these oversight boards, all of the trial sites have paused enrollment of the most critically ill hospitalized patients with COVID-19. A potential for harm in this sub-group could not be excluded. Increased bleeding is a known complication of full-dose anticoagulation. The trials are working urgently to u